1061 related articles for article (PubMed ID: 7922305)
1. Tumor spectrum analysis in p53-mutant mice.
Jacks T; Remington L; Williams BO; Schmitt EM; Halachmi S; Bronson RT; Weinberg RA
Curr Biol; 1994 Jan; 4(1):1-7. PubMed ID: 7922305
[TBL] [Abstract][Full Text] [Related]
2. Use of p53 transgenic mice in the development of cancer models for multiple purposes.
Lubet RA; Zhang Z; Wiseman RW; You M
Exp Lung Res; 2000 Dec; 26(8):581-93. PubMed ID: 11195457
[TBL] [Abstract][Full Text] [Related]
3. Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared 'second hit' on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome.
Srivastava S; Tong YA; Devadas K; Zou ZQ; Sykes VW; Chen Y; Blattner WA; Pirollo K; Chang EH
Oncogene; 1992 May; 7(5):987-91. PubMed ID: 1373881
[TBL] [Abstract][Full Text] [Related]
4. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation.
Venkatachalam S; Shi YP; Jones SN; Vogel H; Bradley A; Pinkel D; Donehower LA
EMBO J; 1998 Aug; 17(16):4657-67. PubMed ID: 9707425
[TBL] [Abstract][Full Text] [Related]
5. A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family.
Plummer SJ; Santibáñez-Koref M; Kurosaki T; Liao S; Noble B; Fain PR; Anton-Culver H; Casey G
Oncogene; 1994 Nov; 9(11):3273-80. PubMed ID: 7936651
[TBL] [Abstract][Full Text] [Related]
6. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
[TBL] [Abstract][Full Text] [Related]
7. Effects of genetic background on tumorigenesis in p53-deficient mice.
Donehower LA; Harvey M; Vogel H; McArthur MJ; Montgomery CA; Park SH; Thompson T; Ford RJ; Bradley A
Mol Carcinog; 1995 Sep; 14(1):16-22. PubMed ID: 7546219
[TBL] [Abstract][Full Text] [Related]
8. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.
Donehower LA; Harvey M; Slagle BL; McArthur MJ; Montgomery CA; Butel JS; Bradley A
Nature; 1992 Mar; 356(6366):215-21. PubMed ID: 1552940
[TBL] [Abstract][Full Text] [Related]
9. Impact of ionizing radiation and genetic background on mammary tumorigenesis in p53-deficient mice.
Backlund MG; Trasti SL; Backlund DC; Cressman VL; Godfrey V; Koller BH
Cancer Res; 2001 Sep; 61(17):6577-82. PubMed ID: 11522657
[TBL] [Abstract][Full Text] [Related]
10. Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome.
Kuperwasser C; Hurlbut GD; Kittrell FS; Dickinson ES; Laucirica R; Medina D; Naber SP; Jerry DJ
Am J Pathol; 2000 Dec; 157(6):2151-9. PubMed ID: 11106587
[TBL] [Abstract][Full Text] [Related]
11. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice.
Harvey M; Vogel H; Morris D; Bradley A; Bernstein A; Donehower LA
Nat Genet; 1995 Mar; 9(3):305-11. PubMed ID: 7773294
[TBL] [Abstract][Full Text] [Related]
12. p53 Testing for Li-Fraumeni and Li-Fraumeni-like syndromes.
Gonzalez K; Fong C; Buzin C; Sommer SS; Saldivar JS
Curr Protoc Hum Genet; 2008 Apr; Chapter 10():Unit 10.10. PubMed ID: 18428420
[TBL] [Abstract][Full Text] [Related]
13. RNA polymerase III transcription can be derepressed by oncogenes or mutations that compromise p53 function in tumours and Li-Fraumeni syndrome.
Stein T; Crighton D; Boyle JM; Varley JM; White RJ
Oncogene; 2002 May; 21(19):2961-70. PubMed ID: 12082526
[TBL] [Abstract][Full Text] [Related]
14. Dominant negative effect of a germ-line mutant p53: a step fostering tumorigenesis.
Srivastava S; Wang S; Tong YA; Hao ZM; Chang EH
Cancer Res; 1993 Oct; 53(19):4452-5. PubMed ID: 8402611
[TBL] [Abstract][Full Text] [Related]
15. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein.
Frebourg T; Kassel J; Lam KT; Gryka MA; Barbier N; Andersen TI; Børresen AL; Friend SH
Proc Natl Acad Sci U S A; 1992 Jul; 89(14):6413-7. PubMed ID: 1631137
[TBL] [Abstract][Full Text] [Related]
16. DNA strand break-sensing molecule poly(ADP-Ribose) polymerase cooperates with p53 in telomere function, chromosome stability, and tumor suppression.
Tong WM; Hande MP; Lansdorp PM; Wang ZQ
Mol Cell Biol; 2001 Jun; 21(12):4046-54. PubMed ID: 11359911
[TBL] [Abstract][Full Text] [Related]
17. Germ-line exclusion of a single p53 allele by premature termination of translation in a Li-Fraumeni syndrome family.
Stolzenberg MC; Brugières L; Gardes M; Dessarps-Freichey F; Chompret A; Bressac B; Lenoir G; Bonaïti-Pellié C; Lemerle J; Feunteun J
Oncogene; 1994 Oct; 9(10):2799-804. PubMed ID: 8084585
[TBL] [Abstract][Full Text] [Related]
18. Mouse Homolog of the Human
Park JH; Li J; Starost MF; Liu C; Zhuang J; Chen J; Achatz MI; Kang JG; Wang PY; Savage SA; Hwang PM
Cancer Res; 2018 Sep; 78(18):5375-5383. PubMed ID: 30042151
[TBL] [Abstract][Full Text] [Related]
19. Mutational and LOH analyses of p53 alleles in colon tumors induced by 1,2-dimethylhydrazine in F1 hybrid mice.
Okamoto M; Ohtsu H; Kominami R; Yonekawa H
Carcinogenesis; 1995 Nov; 16(11):2659-66. PubMed ID: 7586183
[TBL] [Abstract][Full Text] [Related]
20. Allelic phasing of a mouse chromosome 11 deficiency influences p53 tumorigenicity.
Biggs PJ; Vogel H; Sage M; Martin LA; Donehower LA; Bradley A
Oncogene; 2003 May; 22(21):3288-96. PubMed ID: 12761499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]